PARIS, France – 14 November 2025: Coave Therapeutics (“Coave”), a company redefining targeted gene therapy with a best-in-class pipeline powered by ligand-conjugated vectors, today announces the ...
Coave Therapeutics unveils lead gene therapy program for retinal vascular diseases, powered by first-in-class vector for suprachoroidal delivery CoTx-101 represents a potential breakthrough for ...
Powered by Coave's first-in-class proprietary suprachoroidal vector (coAAV-SCS), CoTx-101 represents a potential breakthrough treatment for retinal vascular diseases, combining the three essential ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results